中国肺癌杂志2016，Vol.19Issue(10)：648-652,5.DOI:10.3779/j.issn.1009-3419.2016.10.02
存在驱动基因突变肺鳞癌患者的临床病理特征及预后分析
Driven Gene in Patients with Lung Squamous Cell Carcinoma:Analysis of Clinicopathologic Characteristics and Prognosis
张童童 1李峻岭1
作者信息
- 1. 100021北京，国家癌症中心/中国医学科学院北京协和医学院肿瘤医院
- 折叠
摘要
Abstract
Background and objective It has been proven that epidermal growth factor receptor (EGFR), anaplas-tic lymphoma kinase (ALK), andKARS are common driver genes in non-small cell lung cancer (NSCLC). Molecular targeted therapy increases the overall response rate and progression-free survival (PFS) of patients with EGFR-sensitive mutation or echinoderm microtubule-associated protein like 4-anaplastic lymphoma kinase (EML4-ALK) fusion. However, target and targeted drugs for lung squamous cell carcinoma to indicate clinical therapy remain to be conifrmed. hTe aim of this study was to analyze the relationship between the status of driver genes and the clinicopathologic characteristics of NSCLC.Methods A total of 90 patients were recruited and tested forEGFR,ALK andKARS mutations. hTe status ofEGFR and KARS was tested by ampliifcation refractory mutation system, and the status of ALK was tested by lfuorescence in situ hybridization.Results Of the 90 patients, 8 patients hadEGFR mutation (8.8%), and 2 cases hadKARS mutation (2.2%).EML4-ALK fusion was found in 1 of 18 patients (5.6%).EGFR mutation occurred more frequently in females than in males (P=0.022). Signiifcant differ-ences were observed in pathological stage (P=0.042) and differentiation grade (P=0.003). No signiifcant difference in PFS was observed between EGFR-TKI treatment and chemotherapy inEGFR mutation patients with squamous cell carcinoma of the lung (P=0.607). Patients withEML4-ALK fusion could beneift from targeted therapy.ConclusionEML4-ALK fusion occurred more frequently thanEGFR andKARS mutations in patients with lung squamous cell carcinoma. Clinicopathologic characteristics were different betweenEGFR mutation andEGFR wild-type patients. hTe relationship between molecular tar-geted therapy and status ofEGFR orALK genes in patients with lung squamous cell carcinoma needs further investigation.关键词
肺鳞癌/表皮生长因子受体/间变淋巴瘤激酶/KARS基因Key words
Lung squamous cell carcinoma/Epidermal growth factor receptor/Anaplastic lymphoma kinase/KARS gene引用本文复制引用
张童童,李峻岭..存在驱动基因突变肺鳞癌患者的临床病理特征及预后分析[J].中国肺癌杂志,2016,19(10):648-652,5.
